The preexposure prophylaxis revolution; from clinical trials to programmatic implementation

Purpose of reviewAn investment in preexposure prophylaxis (PrEP) delivery must have public health impact in reducing HIV infections. Sustainable delivery of PrEP requires policy, integration of services, and synergy with other existing HIV prevention programs. This review discusses key policy and programmatic considerations for implementation and scale up of PrEP in Africa. Recent findingsPrEP delivery has been delayed by concerns about adherence and delivery in ‘real world’ settings. Demonstration projects and clinical service delivery models are providing evidence of PrEP effectiveness with an impact much higher than that found in randomized clinical trials. Data confirm that PrEP uptake, adherence, and retention has been high, more so by persons who perceive themselves at high risk for HIV infection, and PrEP is well tolerated. PrEP delivery is more than dispensation of a pill and programs should address other risk drivers, which differ by population. In Africa, barriers to PrEP uptake and adherence include stigma among MSM and low HIV risk perception among young women. Additional data have provided insight into optimal points of service delivery, provider training requirements and quality assurance needs. Of the 2 million new HIV infections in 2014, 70% were in Africa. PrEP use is not lifelong, and use limited to periods of risk may be both effective and cost-effective for the continent. SummaryHIV prevention programs should determine strategies to identify those at substantial risk for HIV infection, formulate and deliver PrEP in combination with interventions that target social drivers of HIV vulnerability specific to each population. Policy guidance for optimal combination of interventions and service delivery avenues, clinical protocols, health infrastructure requirements are required. Cost-effectiveness and efficiency data are essential for policy guidance to navigate ethical questions over use of antiretroviral therapy for HIV-negative individuals when treatment coverage has not been attained in many parts of Africa. Countries need to invest in purposeful advocacy at both local and global forums. Failure to implement PrEP will be a failure to protect future generations.

[1]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[2]  Alison L. Drake,et al.  HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics , 2015, AIDS.

[3]  J. Baeten,et al.  Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. , 2015, AIDS.

[4]  J. Baeten,et al.  Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda , 2015, Journal of the International AIDS Society.

[5]  D. Glidden,et al.  Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. van Damme,et al.  Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial , 2015, PloS one.

[7]  M. Folayan,et al.  “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria , 2015, BMC Public Health.

[8]  N. Mack,et al.  Human Resource Challenges to Integrating HIV Pre-Exposure Prophylaxis (PrEP) into the Public Health System in Kenya: A Qualitative Study. , 2015, African journal of reproductive health.

[9]  J. Baeten,et al.  Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. , 2015, JAMA internal medicine.

[10]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[11]  Megha L Mehrotra,et al.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. , 2014, The Lancet. Infectious diseases.

[12]  A. van der Straten,et al.  Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa , 2014, Journal of the International AIDS Society.

[13]  J. Wilton,et al.  Preparing for PrEP: Perceptions and Readiness of Canadian Physicians for the Implementation of HIV Pre-Exposure Prophylaxis , 2014, PloS one.

[14]  J. Baeten,et al.  My intention was a child but I was very afraid: fertility intentions and HIV risk perceptions among HIV-serodiscordant couples experiencing pregnancy in Kenya , 2014, AIDS care.

[15]  J. Baeten,et al.  HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention , 2014, Journal of acquired immune deficiency syndromes.

[16]  D. Glidden,et al.  HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. , 2014, The Lancet. Infectious diseases.

[17]  N. Sewankambo,et al.  High Incidence of HIV-1 Infection in a General Population of Fishing Communities around Lake Victoria, Uganda , 2014, PloS one.

[18]  T. Bärnighausen,et al.  Concentrated HIV subepidemics in generalized epidemic settings , 2014, Current opinion in HIV and AIDS.

[19]  Alison L. Drake,et al.  Incident HIV during Pregnancy and Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis , 2014, PLoS medicine.

[20]  D. Glidden,et al.  No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis , 2013, PloS one.

[21]  J. Baeten,et al.  Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. , 2013, The Lancet. Infectious diseases.

[22]  L. Bekker,et al.  Men who have sex with men sensitivity training reduces homoprejudice and increases knowledge among Kenyan healthcare providers in coastal Kenya , 2013, Journal of the International AIDS Society.

[23]  J. Baeten,et al.  Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial , 2013, AIDS.

[24]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[25]  A. Ziraba,et al.  Marital status and risk of HIV infection in slum settlements of Nairobi, Kenya: results from a cross-sectional survey. , 2013, African journal of reproductive health.

[26]  Connie Celum,et al.  An Empiric Risk Scoring Tool for Identifying High-Risk Heterosexual HIV-1–Serodiscordant Couples for Targeted HIV-1 Prevention , 2013, Journal of acquired immune deficiency syndromes.

[27]  K. Mayer,et al.  Engaging healthcare providers to implement HIV pre-exposure prophylaxis , 2012, Current opinion in HIV and AIDS.

[28]  Matilu Mwau,et al.  Are slum dwellers at heightened risk of HIV infection than other urban residents? Evidence from population-based HIV prevalence surveys in Kenya , 2012, Health & place.

[29]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[30]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[31]  A. Kamali,et al.  High HIV Incidence and Socio-Behavioral Risk Patterns in Fishing Communities on the Shores of Lake Victoria, Uganda , 2012, Sexually transmitted diseases.

[32]  J. H. van de Wijgert,et al.  HIV Incidence Remains High in KwaZulu-Natal, South Africa: Evidence from Three Districts , 2012, PloS one.

[33]  J. Baeten,et al.  What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant Couples , 2012, Journal of acquired immune deficiency syndromes.

[34]  W. Duffus,et al.  Preexposure Prophylaxis for HIV Infection: Healthcare Providers’ Knowledge, Perception, and Willingness to Adopt Future Implementation in the Southern US , 2012, Southern medical journal.

[35]  L. Bekker,et al.  Identifying At-Risk Populations in Kenya and South Africa: HIV Incidence in Cohorts of Men Who Report Sex With Men, Sex Workers, and Youth , 2012, Journal of acquired immune deficiency syndromes.

[36]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.